Despite significant progress in the treatment of Ph + ALL in recent years, tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 protein have become the most successful targeted therapy for Ph-positive leukemia. Here, ABL1 is linked to acute lymphoblastic leukemia.